India needs closer ties between academia and industry to lead global biopharma

Stakeholders across India's biopharmaceutical sector are calling for deeper engagement between academic institutions and industry players, citing the need to consolidate the country's position in the global market. The collaboration is viewed as instrumental in converting research outputs into commercially viable products and maintaining India's competitive edge in an increasingly crowded international landscape.

Experts argue that strengthened industry-academia ties would facilitate knowledge transfer, improve access to cutting-edge research facilities, and create pathways for emerging talent to transition into the sector. Such partnerships are also expected to accelerate innovation cycles and reduce the time-to-market for new pharmaceutical products and treatments.

Current gaps between academic research and industrial application have been identified as a limiting factor in India's biopharma growth trajectory. Industry representatives have noted that more structured collaboration frameworks could enable institutions to align their research priorities with market demands, while companies gain access to specialized expertise and emerging technologies.

The push for closer partnerships comes as India seeks to strengthen its foothold in high-value biopharmaceutical segments, including biologics and specialty drugs. Enhanced collaboration between universities, research institutions, and pharmaceutical firms is viewed as a key strategy to develop a robust ecosystem that supports innovation, attracts investment, and creates skilled employment opportunities across the sector.